Evidence map›Paper›PMID 27300431›Full record

ArticleCancer cell2016

TRIM-ing Ligand Dependence in Castration-Resistant Prostate Cancer.

Lalit R Patel, Michelle C Barton

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Cancer cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. TRIM15 Exerts Anti-Tumor Effects Through Suppressing Cancer Cell Invasion in Gastric Adenocarcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2018
    Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Lalit R PatelDepartment of Epigenetics and Molecular Carcinogenesis, Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX 77030, USA.
Michelle C BartonDepartment of Epigenetics and Molecular Carcinogenesis, Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX 77030, USA. Electronic address: mbarton@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer is lethal when tumors evolve to activate androgen receptor signaling, which circumvents ligand-deprivation therapy. In this issue of Cancer Cell, Groner et al. show that histone reader and transcription co-regulator TRIM24 occupies a central role in this evolution, nominating inhibitors of TRIM24's bromodomain as a new therapeutic avenue.

Indexed as

HumansLigandsMaleProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantReceptors, AndrogenSignal TransductionTranscription, GeneticLigandsReceptors, Androgen

Identifiers

PMID27300431
OpenAlexW2429357934

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.